Navigation Links
CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
Date:11/14/2011

SAN FRANCISCO, Nov. 14, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented preclinical research results at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in San Francisco, California demonstrating that analogs of novel FAK inhibitor CFAK-C4 disrupted FAK-vascular endothelial growth factor receptor 3 (FAK-VEGFR3) interaction and inhibited pancreatic cancer tumor growth at low concentrations as single agents. The research was conducted by CureFAKtor scientists at the Roswell Park Cancer Institute in Buffalo, New York.

In the poster presentation, Development of Novel FAK Inhibitors Targeting the FAK-VEGFR3 Protein-Protein Interaction Site, CureFAKtor Chief Scientific Officer Dr. William Cance and Senior Scientist Dr. Elena Kurenova reported that oral small molecule FAK inhibitor C4 analogs, C9, C10 and C9A, administered as low dose single agents led to 40 to 60 percent reduction in pancreatic tumor growth in vivo after 30 days of treatment in mouse models. The C4 analogs displayed enhanced potency, minimum toxicity and high specificity for the target site. Abstract C124 will be presented on Tuesday, November 15 from 12:30 to 2:30 pm at West Hall, Level One, Moscone Center West.

"These preclinical results of C4 analogs inhibiting pancreatic tumor growth are very promising and add to our existing C4 data," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals. "We know that FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies."

CureFAKtor Pharmaceuticals recently presented preclinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that FAK inhi
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
3. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
4. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)...  In a policy paper released ... largest lesbian, gay, bisexual and transgender (LGBT) civil ... for Pre-Exposure Prophylaxis (PrEP). PrEP is any medical ... spread of a disease or infection prior to ... drug combination currently approved for PrEP, which protects ...
(Date:10/17/2014)...  Amgen (NASDAQ: AMGN ) today announced ... president of Gladstone Institutes and Gladstone,s Robert W. and ... are pleased to welcome Dr. Sandy Williams ... , chairman and chief executive officer of Amgen. "Dr. ... his direct experience in our industry will both be ...
(Date:10/17/2014)... 2014 According to ... Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic ... Neurology, Oncology, Cardiology) - Global Forecasts to ... Optical Imaging market over the forecast period ... $917.1 million in 2014 and is expected ...
Breaking Medicine Technology:HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... A new report released Wednesday,February 11, 2009 by ... physical activity, Special Olympics athletes are more physically active,than ... , U.S. Vice President Joe ... Winter Games in Boise, Idaho on Thursday, February 12, ...
... Virtua Health has responded to the public regarding legal action ... Court judge ordered Virtua to stop its Top Doc advertising ... advertising statements are fraudulent. Cooper also sent an e-mail to ... "Virtua has always had the highest ethical standards and ...
... , ... Eagan, MN (Vocus) February 11, 2009 -- Employees of DeCare ... Northeastern Minnesota. A company cookbook was created and recipes were gathered ... than 200 cookbooks were sold. , , , , ,"After years ...
... Feb. 11 Cogdell Spencer Inc. (NYSE:, CSA ... of the Northwest,Region for the Company,s wholly owned subsidiary, ... Based in the Company,s Seattle office, Mr. Aigner ... be responsible for all,design-build and development projects in the ...
... with salivary gland , , WEDNESDAY, Feb. 11 (HealthDay News) -- A ... who blew his tuba so hard that he sent air into ... the condition after the boy developed swelling and pain around his ... Deepa Mukundan, who wrote about the case in the Feb. 12 ...
... ("Transition" or the "Company") (TSX: TTH; NASDAQ: ... disease indications with large markets, today announced its financial ... Selected Highlights, -------------------, ... and up to the date of this press,release, the ...
Cached Medicine News:Health News:Special Olympics Issues Report on the Impact of Special Olympics Healthy Athletes Initiative to show Need for Reauthorization of the Special Olympics Sport and Empowerment Act of 2004 2Health News:Special Olympics Issues Report on the Impact of Special Olympics Healthy Athletes Initiative to show Need for Reauthorization of the Special Olympics Sport and Empowerment Act of 2004 3Health News:Virtua Health Responds to Court Order 2Health News:Company Cookbook Proceeds to Benefit United Way of Northeastern Minnesota 2Health News:Cogdell Spencer Announces Aigner as President in the Northwest Region 2Health News:Cogdell Spencer Announces Aigner as President in the Northwest Region 3Health News:Tuba Spells Trouble for Young Musician 2Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 2Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 3Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 4Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 5Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 6Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 7Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 8Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 9Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 10Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 11Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 12Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 13Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 14Health News:Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results 15
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
... Tip flattened and angled 90 1.0mm from end, ... lock high pressure extension tubing set, Capable of ... OD- 1.5mm (.06 in) long luer lock, high ... tubing. Bend 1.0mm from end. (Cannulas ...
Rounded tip for even incisions reducing post-op astigmatism...
Stab incision blades color coded for simple and accurate identification...
Medicine Products: